3 Top Dividend Aristocrats to Buy for 2018
It's quite an honor for a stock to land on the list of Dividend Aristocrats. Income investors like the stability of large-cap stocks that have not only paid out but also increased their dividends for 25 or more years in a row. But some Dividend Aristocrats are better than others.
Several of the nearly 50 Dividend Aristocrats look like good picks as the new year approaches. Which are the best? I'd put Abbott Labs (NYSE: ABT), AbbVie (NYSE: ABBV), and General Dynamics (NYSE: GD) near the top of the list. Here's why these are three top Dividend Aristocrats to buy for 2018.
Image source: Getty Images.
Source: Fool.com
AbbVie Inc. Aktie
177,62 €
1,06 %
Überwältigendes Buy-Interesse für AbbVie Inc.: 33 Buy-Einschätzungen ohne eine einzige Sell-Einschätzung.
Ein positives, aber moderates Potenzial für AbbVie Inc. mit einem Kursziel von 180 € im Vergleich zu 177.62 €.
